Brought to you by 
CAT, Genzyme to develop anti-TGF-beta MAbs
08 Mar 2001
Executive Summary
Genzyme General has licensed exclusive worldwide rights to Cambridge Antibody Technology's fully human anti-TGF-beta monoclonal antibodies for all therapeutic areas, excluding ophthalmology. The partners will co-develop antibodies, primarily for scleroderma treatment, share profits, marketing efforts, and jointly fund R&D.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
CAT, Genzyme to develop anti-TGF-beta MAbs
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice